Abstract
A 'designer drug' that touched off a mysterious epidemic of parkinsonism has provided insights into a basic pathologic process of the disease - destruction of dopaminergic neurons. These insights have also helped correlate clinical approaches with biomedical events, opening the way for development of more effective pharmacologic agents for a still relentlessly progressive disorder.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 107-138 |
| Number of pages | 32 |
| Journal | Hospital Practice |
| Volume | 22 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1987 |
ASJC Scopus subject areas
- Medicine(all)